Spherix tests Naturlose in fighting oral plaque
The revolutionary product is doubly patented for use as an active drug and as a low-calorie sweetener in drugs to increase their palatability.
31/03/05 The BioSpherix Division of Spherix Incorporated has announced that human clinical trials had begun to test Naturlose, the Firm’s unique, naturally-occurring sugar, in fighting oral plaque.
BioSpherix believes that the trials, being conducted by the University of Maryland School of Dentistry, will provide human validation of the Firm’s own laboratory tests. They demonstrated Naturlose’s ability to prevent oral bacteria from forming plaque, and to destroy any plaque already formed. The Firm’s revolutionary product is doubly patented for use as an active drug and as a low-calorie sweetener in drugs to increase their palatability.
In the clinical trials, people known to form dental plaque will be chosen as subjects. At the start of the trial, their plaque levels will be reduced to zero by mechanical dental procedures. Using FDA-approved plaque-measuring techniques, the investigators will monitor and compare the effects of a Naturlose mouth rinse, a water mouth rinse, and a standard plaque-reducing chemical mouth rinse on the teeth and gums. The subjects will not know which mouth rinse they are using. They will be instructed to use only the given mouth rinse, with no tooth brushing, flossing, or other plaque removal technique for the multiple test periods as prescribed by the University of Maryland School of Dentistry investigators. The tests will be performed to FDA standards.
